Other


MULTIPLE AWARDS

Individual applicants may only receive one award from the CF RIA program per cycle.

MULTIPLE AWARDS FROM THE SAME INSTITUTION

More than one application from the same institution (i.e. university, hospital) is permitted.

CHANGE IN AWARD RECIPIENT'S STATUS

The transfer of an award to another institution will be at the discretion of the CF RIA program, as well as agreement between the current and new institution. Additionally, a contract with the new institution will be required.

START AND END DATES

Research should commence upon successful execution of the contract, unless an alternative date for commencement has been approved by the steering committee. Failure to initiate the research within this period may result in the withdrawal of the award.

Projects should be completed within 24 months (mentored award) or 36 months (independent award) of commencement. In the event that your research will not be completed within the project period, a no-cost extension request will be considered for approval by the steering committee upon receipt of a no-cost extension application form.

RECOMBINANT MOLECULES AND/OR ANIMAL AND HUMAN SUBJECTS

Applicants requesting an award to carry out research with recombinant molecules and/or animal or human subjects must obtain and show proof of the required approvals from all appropriate authorities. If an applicant’s institution does not require special permission for using recombinant molecules, then this must be communicated to the CF RIA secretariat.

The CF RIA secretariat must receive copies of appropriate permissions before any award funds will be disbursed.

The applicant’s institution has responsibility for ensuring that research is conducted in accordance with applicable requirements, including, but not limited to, good clinical practices (GCP) and good laboratory practices (GLP).

PrivacyTerms of Use
© 2017 Vertex Pharmaceuticals Incorporated | VXMA-HQ-92-00065 | 10/2017
Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated